Celiac Drugs in Development Series / Drug 1
Understanding Celiac Disease
Celiac disease, whick is characterized by an immune reaction to gluten,a protein found in wheat, barley, and rye affects approximately 1% of the global population.
When individuals with celiac diease consume gluten, their immune system responds by attacking the lining of the small intestine. This immune reaction damages the lining of the small intestine which can lead to a range of symptoms, that commonly include abdominal pain, diarrhea, fatigue, and nutritional deficiencies.
Currently, the standard of care is a strict gluten-free diet, requiring individuals to avoid all sources of gluten. Adhering to a gluten-free can be challenging and can lead to a reduced quality of life for those with celiac disease.
Accidental gluten exposure is common, even for those who strickly follow the diet.
The Need for a Drug-Based Treatment
Researchers and pharmacceutical companies have been working to develop drugs that can provide relief for individuals with celiac disease, allowing them to consume gluten without triggering an immune response.
The Potential of KAN-101
One promising drug in development is KAN-101. Anokion is developing KAN-101, an investigational treatment for celiac disease.
This novel drug targets the underlying mechanisms of celiac disease by aiming to reduce the immune response triggered by gluten ingestion. KAN-101 is a small molecule drug that acts as an inhibitor of certain immune cells and enzymes involved in the immune response triggerd by gluten.
KAN-101 as well as other drugs in development have shown promising results so far. And many are in phase one and two clinical trials.
Additonal Information from GFT:
This article kicks off our 'Celiac Drugs in Development Series, where we take a deep dive into eight drugs in development.
For a closer look at this article you can see it in https://medium.com/@lreynolds/drug-based-treatment-for-celiac-disease-c83e4338d932 or https://www.glutenfreetherapeutics.com/living-gluten-free/medicine-research/drug-based-treatment-for-celiac-disease/
Leigh Reynolds is the owner of both Reynolds Marketing and Gluten Free Therapeutics.